Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 12, 2006

View Archived Issues

Chugai presents nonsteroidal androgen receptor antagonist for the treatment of prostate cancer

Snapshots of recent clinical trials in neuro-oncology

Glycolysis inhibition by 2-deoxy-D-glucose may be a novel antiepileptic strategy

Pfizer's orally active Cdk4/6 inhibitor PD-0332991 shows potential for myeloma therapy

Preclinical results suggest potential use of Pfizer's MEK inhibitor PD-0325901 in myeloid leukemia

ArQule updates program status

Intercell to acquire Pelias

AVX-13619 demonstrates antibacterial activity in systemic model

Avicena signs agreement with NINDS for phase III trial of PD-02

PanGenetics licenses antibody for treatment of pain from Lay Line Genomics

Xenon and Roche partner on protein therapeutics targeting hemojuvelin

Eltrombopag studied for ITP in long-term phase III study

rEV-131 fails to meet primary endpoint in phase IIb allergic rhinitis study

AC Immune and Genentech enter agreement for anti-beta-amyloid antibodies

Emergency contraceptive Ella begins phase III study

Lexapro provides greater reduction in MADRS scores than Cymbalta in MDD

PRTX-100 inhibits platelet phagocytosis in an in vitro model of ITP

Positive findings for Nastech's insulin nasal spray formulations

Iloperidone demonstrates statistical significance in schizophrenia

HuMax-CD20 produces positive ACR and EULAR responses in RA patients

Phenoxazine derivatives as new antimalarial drugs

Evista filed for reduction of invasive breast cancer in postmenopausal women

Velcade approved for relapsed mantle cell lymphoma

Orphan drug designation in renal cancer recommended for TroVax in E.U.

NDA submitted for telavancin in treatment of cSSSI

Recent patents reveal novel antiarthritic agents

Synordia European application withdrawn

Recent patents report new therapeutic agents for endocrine-related disorders

Novel agents for treating neurological disorders disclosed in recent Neuren and Santhera patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...